Details of the Drug

General Information of Drug (ID: DML53ZJ)

Drug Name

Mirtazapine

Synonyms

Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1], [2]

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

265.35

Topological Polar Surface Area (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The total body clearance of drug is 1 L/h [4]
Elimination: This drug is mainly excreted by the kidney. It is 75% eliminated in the urine and 15% eliminated in the feces [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 20 - 40 hours [5]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.82634 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.15% [7]
Vd: The volume of distribution (Vd) of drug is 107 +/- 42 L [8]
Water Solubility: The ability of drug to dissolve in water is measured as 0.5 mg/mL [3]

Chemical Identifiers

Formula: C17H19N3
IUPAC Name: 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
Canonical SMILES: CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
InChI: InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChIKey: RONZAEMNMFQXRA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4205
ChEBI ID: CHEBI:6950
CAS Number: 85650-52-8
DrugBank ID: DB00370
TTD ID: D05ZIK
INTEDE ID: DR1098
ACDINA ID: D00439

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Antagonist	[9], [10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[12]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[13]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Depression

ICD Disease Classification

6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 2C receptor (HTR2C)	DTT	HTR2C	1.02E-02	-0.45	-0.37
5-HT 2C receptor (HTR2C)	DTT	HTR2C	2.27E-01	0.27	0.6
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.94E-01	-1.03E-01	-3.08E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	7.37E-02	9.49E-02	8.07E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.73E-02	6.49E-02	3.07E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.45E-01	2.07E-02	1.74E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.59E-01	6.29E-02	3.14E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	4.84E-01	-8.38E-02	-8.46E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	8.99E-01	-6.93E-03	-1.36E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	9.21E-01	7.31E-03	6.10E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mirtazapine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aprepitant	DM053KT	Moderate	Decreased metabolism of Mirtazapine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[63]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Mirtazapine and Sertraline.	Depression [6A70-6A7Z]	[64]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Mirtazapine and Trimipramine.	Depression [6A70-6A7Z]	[64]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Mirtazapine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[64]
Imipramine	DM2NUH3	Major	Additive serotonergic effects by the combination of Mirtazapine and Imipramine.	Depression [6A70-6A7Z]	[64]
Fluoxetine	DM3PD2C	Major	Additive serotonergic effects by the combination of Mirtazapine and Fluoxetine.	Depression [6A70-6A7Z]	[64]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of Mirtazapine and Nortriptyline.	Depression [6A70-6A7Z]	[64]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Mirtazapine and Vilazodone.	Depression [6A70-6A7Z]	[64]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Mirtazapine and Nefazodone.	Depression [6A70-6A7Z]	[64]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Mirtazapine and Paroxetine.	Depression [6A70-6A7Z]	[64]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Mirtazapine and Selegiline.	Depression [6A70-6A7Z]	[65]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Mirtazapine and Vortioxetine.	Depression [6A70-6A7Z]	[64]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of Mirtazapine and Duloxetine.	Depression [6A70-6A7Z]	[64]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Mirtazapine and Isocarboxazid.	Depression [6A70-6A7Z]	[65]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Mirtazapine and Milnacipran.	Depression [6A70-6A7Z]	[64]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Escitalopram.	Depression [6A70-6A7Z]	[66]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Mirtazapine and Tranylcypromine.	Depression [6A70-6A7Z]	[65]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Mirtazapine and Desvenlafaxine.	Depression [6A70-6A7Z]	[64]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Mirtazapine and Phenelzine.	Depression [6A70-6A7Z]	[65]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Mirtazapine and Clomipramine.	Depression [6A70-6A7Z]	[64]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Mirtazapine and Trazodone.	Depression [6A70-6A7Z]	[64]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of Mirtazapine and Amoxapine.	Depression [6A70-6A7Z]	[64]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Mirtazapine and Doxepin.	Depression [6A70-6A7Z]	[64]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Mirtazapine and Maprotiline.	Depression [6A70-6A7Z]	[64]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Esketamine.	Depression [6A70-6A7Z]	[67]
-----------


⏷ Show the Full List of 25 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mirtazapine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Mirtazapine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[68]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[69]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Idarubicin.	Acute myeloid leukaemia [2A60]	[70]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[70]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Mirtazapine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[70]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[71]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Oliceridine.	Acute pain [MG31]	[70]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Mirtazapine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[70]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Tacrine.	Alzheimer disease [8A20]	[72]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Galantamine.	Alzheimer disease [8A20]	[72]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Rivastigmine.	Alzheimer disease [8A20]	[72]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Mirtazapine and Metronidazole.	Amoebiasis [1A36]	[67]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Ivabradine.	Angina pectoris [BA40]	[73]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Bepridil.	Angina pectoris [BA40]	[72]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Dronedarone.	Angina pectoris [BA40]	[72]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[74]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of Mirtazapine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[64]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Cilostazol.	Arterial occlusive disease [BD40]	[70]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Mirtazapine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[63]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Mirtazapine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[63]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Levalbuterol.	Asthma [CA23]	[75]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Terbutaline.	Asthma [CA23]	[76]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Pirbuterol.	Asthma [CA23]	[76]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Mirtazapine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[63]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[73]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Mirtazapine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[64]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Mirtazapine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[77]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[70]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Mirtazapine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[63]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Mirtazapine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[70]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Mirtazapine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[63]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Mirtazapine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[72]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Mirtazapine and Linezolid.	Bacterial infection [1A00-1C4Z]	[78]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[70]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[70]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Mirtazapine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[63]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Loperamide.	Bowel habit change [ME05]	[79]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Eribulin.	Breast cancer [2C60-2C6Y]	[70]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Lapatinib.	Breast cancer [2C60-2C6Y]	[70]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Mirtazapine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[63]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[70]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Toremifene.	Breast cancer [2C60-2C6Y]	[72]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Bosutinib.	Breast cancer [2C60-2C6Y]	[70]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Sotalol.	Cardiac arrhythmia [BC9Z]	[72]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[80]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[76]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[75]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[76]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[76]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[76]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Mirtazapine caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[70]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Mirtazapine and Dihydrocodeine.	Chronic pain [MG30]	[81]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Mirtazapine and Levomilnacipran.	Chronic pain [MG30]	[64]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Oxaliplatin.	Colorectal cancer [2B91]	[70]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Isoproterenol.	Conduction disorder [BC63]	[75]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Olopatadine.	Conjunctiva disorder [9A60]	[82]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Halothane.	Corneal disease [9A76-9A78]	[70]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Propofol.	Corneal disease [9A76-9A78]	[83]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Sevoflurane.	Corneal disease [9A76-9A78]	[70]
Alfentanil	DMVO0UB	Major	Additive serotonergic effects by the combination of Mirtazapine and Alfentanil.	Corneal disease [9A76-9A78]	[64]
Remifentanil	DMZTXCH	Major	Additive serotonergic effects by the combination of Mirtazapine and Remifentanil.	Corneal disease [9A76-9A78]	[64]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Probucol.	Coronary atherosclerosis [BA80]	[70]
Dextromethorphan	DMUDJZM	Major	Additive serotonergic effects by the combination of Mirtazapine and Dextromethorphan.	Cough [MD12]	[64]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Mifepristone.	Cushing syndrome [5A70]	[72]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Pasireotide.	Cushing syndrome [5A70]	[72]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Mirtazapine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[63]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Mirtazapine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[84]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Ethanol.	Cystitis [GC00]	[82]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Mirtazapine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[63]
Griseofulvin	DMK54YG	Moderate	Increased metabolism of Mirtazapine caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[70]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Mirtazapine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[85]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[72]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Mirtazapine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[64]
Primidone	DM0WX6I	Moderate	Increased metabolism of Mirtazapine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[70]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Mirtazapine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[70]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Mirtazapine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[63]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Mirtazapine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[70]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Mirtazapine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[70]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Mirtazapine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[70]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Mirtazapine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[70]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Mirtazapine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[63]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Mirtazapine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[63]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Pentamidine.	Fungal infection [1F29-1F2F]	[70]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Mirtazapine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[63]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Mirtazapine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[63]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Mirtazapine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[63]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[72]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[70]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Brimonidine.	Glaucoma [9C61]	[86]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Mirtazapine caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[70]
Ergotamine	DMKR3C5	Major	Additive serotonergic effects by the combination of Mirtazapine and Ergotamine.	Headache [8A80-8A84]	[64]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Mirtazapine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[63]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Mirtazapine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[63]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Mirtazapine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[84]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Mirtazapine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[70]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Mirtazapine and Procarbazine.	Hodgkin lymphoma [2B30]	[65]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Mirtazapine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Mirtazapine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Mirtazapine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[87]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[88]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Mirtazapine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Mirtazapine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Mirtazapine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Mirtazapine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Mirtazapine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Mirtazapine caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[63]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Mirtazapine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[63]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Mirtazapine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[63]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Mirtazapine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[63]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[72]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[72]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Crizotinib.	Lung cancer [2C25]	[89]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Mirtazapine and Porfimer Sodium.	Lung cancer [2C25]	[90]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Ceritinib.	Lung cancer [2C25]	[72]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Mirtazapine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[70]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Mirtazapine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Osimertinib.	Lung cancer [2C25]	[91]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Mirtazapine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Selpercatinib.	Lung cancer [2C25]	[73]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Lumefantrine.	Malaria [1F40-1F45]	[67]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Halofantrine.	Malaria [1F40-1F45]	[92]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Chloroquine.	Malaria [1F40-1F45]	[93]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Hydroxychloroquine.	Malaria [1F40-1F45]	[93]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Quinine.	Malaria [1F40-1F45]	[70]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Primaquine.	Malaria [1F40-1F45]	[70]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[73]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Mirtazapine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[63]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Mirtazapine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[63]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[94]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Vemurafenib.	Melanoma [2C30]	[72]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and LGX818.	Melanoma [2C30]	[95]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Mirtazapine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[73]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[96]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Mirtazapine and Almogran.	Migraine [8A80]	[64]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Mirtazapine and Frovatriptan.	Migraine [8A80]	[64]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Mirtazapine and Rizatriptan.	Migraine [8A80]	[64]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Mirtazapine and Naratriptan.	Migraine [8A80]	[64]
Sumatriptan	DMVYXR8	Major	Additive serotonergic effects by the combination of Mirtazapine and Sumatriptan.	Migraine [8A80]	[64]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Mirtazapine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[63]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Flibanserin.	Mood disorder [6A60-6E23]	[97]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Thalidomide.	Multiple myeloma [2A83]	[98]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Siponimod.	Multiple sclerosis [8A40]	[67]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Mirtazapine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[70]
Methoxsalen	DME8FZ9	Moderate	Decreased metabolism of Mirtazapine caused by Methoxsalen mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[63]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Romidepsin.	Mycosis fungoides [2B01]	[70]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[72]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Mirtazapine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[63]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[70]
Modafinil	DMYILBE	Moderate	Increased metabolism of Mirtazapine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[70]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Droperidol.	Nausea/vomiting [MD90]	[72]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Mirtazapine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[63]
Palonosetron	DMBHMOX	Major	Additive serotonergic effects by the combination of Mirtazapine and Palonosetron.	Nausea/vomiting [MD90]	[72]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Mirtazapine and Granisetron.	Nausea/vomiting [MD90]	[72]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Dolasetron.	Nausea/vomiting [MD90]	[72]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Mirtazapine and Ondansetron.	Nausea/vomiting [MD90]	[72]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Mirtazapine and Bupropion.	Nicotine use disorder [6C4A]	[99]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Entrectinib.	Non-small cell lung cancer [2C25]	[67]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Mirtazapine and Sibutramine.	Obesity [5B80-5B81]	[100]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Mirtazapine and Lorcaserin.	Obesity [5B80-5B81]	[101]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Mirtazapine and Dexfenfluramine.	Obesity [5B80-5B81]	[64]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[73]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Lofexidine.	Opioid use disorder [6C43]	[72]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Apraclonidine.	Optic nerve disorder [9C40]	[86]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Mirtazapine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[67]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Rucaparib.	Ovarian cancer [2C73]	[70]
Pentazocine	DM1XBHS	Major	Additive serotonergic effects by the combination of Mirtazapine and Pentazocine.	Pain [MG30-MG3Z]	[64]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Mirtazapine and Oxymorphone.	Pain [MG30-MG3Z]	[81]
Levorphanol	DMGS80V	Moderate	Additive serotonergic effects by the combination of Mirtazapine and Levorphanol.	Pain [MG30-MG3Z]	[81]
Nalbuphine	DMOSQGU	Moderate	Additive serotonergic effects by the combination of Mirtazapine and Nalbuphine.	Pain [MG30-MG3Z]	[81]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Mirtazapine and Buprenorphine.	Pain [MG30-MG3Z]	[81]
Hydrocodone	DMQ2JO5	Moderate	Additive serotonergic effects by the combination of Mirtazapine and Hydrocodone.	Pain [MG30-MG3Z]	[81]
Meperidine	DMX4GND	Major	Additive serotonergic effects by the combination of Mirtazapine and Meperidine.	Pain [MG30-MG3Z]	[64]
Oxycodone	DMXLKHV	Moderate	Additive serotonergic effects by the combination of Mirtazapine and Oxycodone.	Pain [MG30-MG3Z]	[81]
Thiabendazole	DM7YCK3	Moderate	Decreased metabolism of Mirtazapine caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[63]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Triclabendazole.	Parasitic worm infestation [1F90]	[70]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Mirtazapine and Safinamide.	Parkinsonism [8A00]	[65]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Mirtazapine and Rasagiline.	Parkinsonism [8A00]	[65]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Pimavanserin.	Parkinsonism [8A00]	[102]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Mirtazapine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[103]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Mirtazapine and Lindane.	Pediculosis [1G00]	[104]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Famotidine.	Peptic ulcer [DA61]	[67]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[105]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Lefamulin.	Pneumonia [CA40]	[106]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Mirtazapine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[63]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Ritodrine.	Preterm labour/delivery [JB00]	[76]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Degarelix.	Prostate cancer [2C82]	[73]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and ABIRATERONE.	Prostate cancer [2C82]	[73]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Nilutamide.	Prostate cancer [2C82]	[73]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Mirtazapine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[70]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Flutamide.	Prostate cancer [2C82]	[73]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Relugolix.	Prostate cancer [2C82]	[73]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Bicalutamide.	Prostate cancer [2C82]	[73]
Levomepromazine	DMIKFEL	Moderate	Decreased metabolism of Mirtazapine caused by Levomepromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[63]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Mirtazapine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[70]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Sorafenib.	Renal cell carcinoma [2C90]	[70]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[107]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Mirtazapine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[108]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Mirtazapine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[70]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Mirtazapine caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[70]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Quetiapine.	Schizophrenia [6A20]	[72]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Mesoridazine.	Schizophrenia [6A20]	[72]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Thioridazine.	Schizophrenia [6A20]	[72]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Iloperidone.	Schizophrenia [6A20]	[72]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Haloperidol.	Schizophrenia [6A20]	[72]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Amisulpride.	Schizophrenia [6A20]	[109]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Asenapine.	Schizophrenia [6A20]	[72]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Pimozide.	Schizophrenia [6A20]	[73]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Mirtazapine and Fentanyl.	Sensation disturbance [MB40]	[64]
Sufentanil	DMU7YEL	Major	Additive serotonergic effects by the combination of Mirtazapine and Sufentanil.	Sensation disturbance [MB40]	[64]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[70]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Mirtazapine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[63]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Mirtazapine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[73]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Mirtazapine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[63]
Armodafinil	DMGB035	Moderate	Increased metabolism of Mirtazapine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[70]
LEE011	DMMX75K	Moderate	Decreased metabolism of Mirtazapine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[63]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[70]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[72]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[73]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[70]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Mirtazapine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[73]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[70]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Mirtazapine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[72]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Mirtazapine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[110]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Lenvatinib.	Thyroid cancer [2D10]	[70]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Papaverine.	Tonus and reflex abnormality [MB47]	[111]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Mirtazapine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[112]
Enoxacin	DMYTE6L	Moderate	Decreased metabolism of Mirtazapine caused by Enoxacin mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[63]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Mirtazapine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[70]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[70]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[113]
Mexiletine	DMCTE9R	Moderate	Decreased metabolism of Mirtazapine caused by Mexiletine mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[63]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[72]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[70]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Mirtazapine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[70]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Mirtazapine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[72]
-----------


⏷ Show the Full List of 237 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Alpha-tocopherol	E00243	14985	Antimicrobial preservative; Antioxidant
Aspartame	E00402	134601	Flavoring agent
Caryophyllene	E00471	5281515	Flavoring agent
Dimethyl benzyl carbinyl acetate	E00196	9024	Adsorbent; Flavoring agent
Ethyl butyrate	E00153	7762	Flavoring agent
FD&C blue no. 2	E00446	2723854	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Acetaldehyde	E00003	177	Flavoring agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant
--------------------


⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mirtazapine 15 mg tablet	15 mg	Disintegrating Oral Tablet	Oral
Mirtazapine 30 mg tablet	30 mg	Disintegrating Oral Tablet	Oral
Mirtazapine 45 mg tablet	45 mg	Disintegrating Oral Tablet	Oral
Mirtazapine 15 mg tablet	15 mg	Oral Tablet	Oral
Mirtazapine 45 mg tablet	45 mg	Oral Tablet	Oral
Mirtazapine 30 mg tablet	30 mg	Oral Tablet	Oral
Mirtazapine 7.5 mg tablet	7.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7241).
2	Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3	BDDCS applied to over 900 drugs
4	Timmer CJ, Sitsen JM, Delbressine LP: Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000 Jun;38(6):461-74. doi: 10.2165/00003088-200038060-00001.
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Bioavailability of mirtazapine from Remeron? tablets after single and multiple oral dosing
9	Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
10	Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
11	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
14	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
25	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
26	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
27	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
28	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
29	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
31	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
32	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
33	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
34	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
35	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
36	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
37	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
38	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
39	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
40	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
41	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
42	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
43	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
44	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
45	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
46	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
47	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
48	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
49	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
50	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
51	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
52	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
53	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
54	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
55	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
56	The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
57	Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
58	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
59	Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
60	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
61	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
62	The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
63	Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
64	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
65	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
66	Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
67	Cerner Multum, Inc. "Australian Product Information.".
68	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
69	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
70	Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
71	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
72	Canadian Pharmacists Association.
73	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
74	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
75	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
76	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
77	Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
78	Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
79	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
80	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
81	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
82	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
83	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
84	Sitsen JM, Maris FA, Timmer CJ "Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects." Eur J Drug Metab Pharmacokinet 26 (2001): 109-21. [PMID: 11554425]
85	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
86	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
87	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
88	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
89	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
90	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
91	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
92	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
93	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
94	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
95	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
96	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
97	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
98	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
99	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
100	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
101	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
102	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
103	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
104	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
105	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
106	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
107	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
108	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
109	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
110	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
111	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
112	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
113	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.